|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-5-28
|
|
pubmed:abstractText |
To define the maximum tolerated dose (MTD) and the nature of the toxicities associated with gemcitabine given as a short infusion to patients with non-small cell lung cancer (NSCLC). Secondary objectives were to monitor immunologic response, clinical response, and survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
pubmed-author:FersonP FPF,
pubmed-author:FribergDD,
pubmed-author:GoodingW EWE,
pubmed-author:KasselAA,
pubmed-author:KeenanRR,
pubmed-author:LandreneauR JRJ,
pubmed-author:LevickS NSN,
pubmed-author:LindbergC ACA,
pubmed-author:MiketicL MLM,
pubmed-author:PonasR SRS,
pubmed-author:SabatineJ MJM,
pubmed-author:TarasoffPP,
pubmed-author:TrennM RMR,
pubmed-author:WhitesideT LTL,
pubmed-author:YousemS ASA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
335-44
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15165093-Adenocarcinoma,
pubmed-meshheading:15165093-Adult,
pubmed-meshheading:15165093-Aged,
pubmed-meshheading:15165093-Antimetabolites, Antineoplastic,
pubmed-meshheading:15165093-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15165093-Carcinoma, Squamous Cell,
pubmed-meshheading:15165093-Cytokines,
pubmed-meshheading:15165093-Deoxycytidine,
pubmed-meshheading:15165093-Female,
pubmed-meshheading:15165093-Granulocytes,
pubmed-meshheading:15165093-Humans,
pubmed-meshheading:15165093-Infusions, Intravenous,
pubmed-meshheading:15165093-Lung Neoplasms,
pubmed-meshheading:15165093-Male,
pubmed-meshheading:15165093-Maximum Tolerated Dose,
pubmed-meshheading:15165093-Middle Aged,
pubmed-meshheading:15165093-Superoxides
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
|
|
pubmed:affiliation |
Institute of Oncology, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel. mllevitt@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
